FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks
Go back to FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 22.60 +0.51 (2.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $22.09 | 52 Week High | $42.49 | |||
| Open | $22.26 | 52 Week Low | $16.64 | |||
| Day High | $22.66 | P/E | N/A | |||
| Day Low | $22.01 | EPS | $-0.42 | |||
| Volume | 1,476,897 | |||||
